Latest Research And Development News

Patrys has moved its injectable quetiapine program into human testing, while its FY2026 annual report warns the company will need further funding within 12 months. The company ended the year with $3.36 million in cash after raising capital and acquiring the RLS-2202 development program.

AnteoTech reduced its FY2026 loss and strengthened its balance sheet, but auditors warned that a material uncertainty remains over the company’s ability to continue as a going concern. Commercial revenue fell sharply as battery and diagnostics opportunities remained largely in evaluation or negotiation.

ABx Group has lodged a prospectus for a fully underwritten $2 million share purchase plan, forming part of a broader $4.1 million capital raising for its Deep Leads rare earths project and ALCORE pilot plant. The offer gives eligible shareholders discounted shares and options, but leaves the final price unknown until after applications close and remains subject to shareholder approval.

EMVision Medical Devices has received a $4.3 million R&D tax refund, adding non-dilutive funding as it progresses clinical work on its emu™ and First Responder devices. The cash arrives against a last reported cash balance of $17.1 million and $4.6 million in remaining grant funding at 30 June 2026.

First Graphene expanded its product range and international footprint in FY2026, lifting revenue while narrowing its annual loss. But the company says continued operations depend on securing further equity funding, putting commercial execution and liquidity at the centre of its next phase.

Energy Action Limited (ASX:EAX) expanded its contracted forward revenue and cash pipeline in FY2026, but the growth was not yet visible in earnings. Revenue was broadly flat while net profit fell 78% and EBITDA declined 27%.

Latrobe Magnesium has moved its demonstration plant into the final installation stage for magnesium metal, but its annual report flags a material uncertainty over whether the loss-making group can continue as a going concern. The company had $1.09 million in cash at 30 June and has since secured an $8.5 million equity raising to fund commissioning and corporate costs.

Adisyn has moved closer to commercialising its graphene platform after independently verified sub-300°C deposition, a US patent allowance and a new defence technology arm. The progress came alongside a A$7.83 million statutory loss, A$4.47 million in operating cash outflows and a heavily judgement-based A$42.1 million technology asset.

Immuron delivered record FY26 sales, a narrower loss and a much stronger cash balance, while shifting clinical development towards commercial partners. The annual report also flags a material weakness in inventory controls and confirms that IMM-529 remains dependent on a future licensing deal.

Legacy Minerals enters FY2027 with a larger Mt Carrington resource, a positive preliminary development study and fresh drilling underway, but the proposed mine still requires substantial funding. The ASX-listed explorer reported a A$1.85 million FY2026 loss and held A$6.07 million in cash at year-end.

PaySauce has moved its Global Payroll Platform from development into commercial operation in Australia, while first-quarter FY27 ARR rose 8% to $9.5 million. The expansion is supported by a stronger cash position, but higher customer acquisition costs and lower profitability leave execution firmly in focus.

International Graphite has arranged approximately $1.5 million in non-dilutive finance with National Australia Bank to fund construction of its Collie graphite processing facility. The project remains targeted for production building completion in Q2 2027, but the funding adds future repayment obligations as the company moves closer to commissioning.